Latest Content

  • On-demand Webinar: Value of Real-world Evidence and Synthetic Control Arms

    On-demand Webinar: Value of Real-world Evidence and Synthetic Control Arms

    Learn about the benefits that Real-World Evidence (RWE) can bring to small & mid-size biopharmaceutical companies.

    Watch Webinar
  • ×

    Register now for access to the Parexel Biotech Content Hub

    First Name
    Last Name
    Company Name
    Job Title
    Country
    Thank you!
    Error - something went wrong!
  • Genomics & biomarkers: Answers in the blood2:53

    Genomics & biomarkers: Answers in the blood

    Parexel’s Anita Nelsen, SVP, Translational Medicine and Michelle Hoiseth, Chief Data Officer, Corporate VP speak with Ashley Druckenmiller about caring with her two sons with hemophilia and the benefi

    Watch Video
  • Cellular and gene therapies: for biotechs, collaboration is key to successful innovation

    Cellular and gene therapies: for biotechs, collaboration is key to successful innovation

    Learn more about what to look for in the right CRO partner to overcome logistical and operational challenges in cell and gene therapy product development.

    Read More
  • Podcast: Opportunities for biotechs in precision medicine, driving value and bringing important new therapies to patients

    Podcast: Opportunities for biotechs in precision medicine, driving value and bringing important new therapies to patients

    Parexel precision medicine experts Angela Qu and Arlene Hughes join host Alberto Grignolo to discuss how biotech companies can incorporate precision medicine into their development plans.

    Learn More
  • Endpoints That Matter2:39

    Endpoints That Matter

    Learn why capturing meaningful endpoints during the drug development process means a better quality of life for patients.

    Watch Video
  • ×

    Tell Us About Your Biotech Goals.

    What are your top priorities for 2020?
    Thank you!
    Error - something went wrong!
  • Rare disease and orphan drug designations - What you need to know

    Rare disease and orphan drug designations - What you need to know

    Collectively, rare diseases affect over 30 million Americans.  The Orphan Drug Act (ODA), which provides the statutory basis for FDA to designate a drug or biologic agent as a therapy for a...

    Learn More
  • Commercial and regulatory strategy considerations for biotech

    Commercial and regulatory strategy considerations for biotech

    In this blog, Parexel regulatory and strategy experts tackle the question of how we can ensure that worthy innovations in the biotech pipeline make it to patients sooner.

    Learn More
  • Rescuing Product Approvals from Data Integrity Issues

    Rescuing Product Approvals from Data Integrity Issues

    The pharmaceutical industry is inundated with a plethora of communications about data integrity. Let's look at at one of these situations where applicant holders face these issues successfully.

    Learn More
  • Parexel Biotech – a patient-centric approach is in our DNA4:24

    Parexel Biotech – a patient-centric approach is in our DNA

    Hear firsthand from Monica about her personal journey as a clinical trial participant to understand the value of easing patient burden

    Watch Video
  • Parexel Biotech – designed with biotech’s unique way of working in mind2:55

    Parexel Biotech – designed with biotech’s unique way of working in mind

    James Anthony, SVP, Global Head Biotech and Graciela Rácaro, SVP, Global Head, Biotech Operations, both from Parexel, discuss how Parexel Biotech has been built to meet customer and patient needs

    Watch Video
  • Plan & Engage Early to Manage the Risks of Risk Management

    Plan & Engage Early to Manage the Risks of Risk Management

    Read More
  • Improving Drug Development & Patient Access With the Right People, Processes, and Culture

    Improving Drug Development & Patient Access With the Right People, Processes, and Culture

    Learn More
  • Learn about Parexel® Biotech

    Learn about Parexel® Biotech

    Focused on meeting customer and the patient needs with tailored, flexible solutions that speed up development and increase the likelihood of launch so that we get treatments into the hands of patients

    Read More
  • Three Keys To Mitigating Risk In Adaptive Trials

    Three Keys To Mitigating Risk In Adaptive Trials

    Read More
  • Drug development innovations that work: Adaptive trial design - BioPharma Dive

    Drug development innovations that work: Adaptive trial design - BioPharma Dive

    Read More
  • Opportunities for biotechs in precision medicine: bringing important new therapies to patients and value to the company

    Opportunities for biotechs in precision medicine: bringing important new therapies to patients and value to the company

    For biotech companies, precision medicine holds tremendous promise for innovation – for newly designed drugs, new technologies for drug delivery, and engineered cell or gene therapies.

    Read More
  • The hidden value of early patient centricity: practical solutions for early phase trials

    The hidden value of early patient centricity: practical solutions for early phase trials

    Learn about five economical and efficient ways to make early phase trials both patient-centric and more effective.

    Read More
  • Venturing into a new era of CNS drug development to improve success

    Venturing into a new era of CNS drug development to improve success

    Three strategies that apply multidisciplinary solutions earlier in the development process to reduce failures and accelerate CNS drug development.

    Read More
  • loading
    Loading More...